Abstract
This study aimed to predict the preventive effect of clopidogrel against recurrent cardiovascular events (CVEs) among the Arab population carrying different CYP2C19 mutations and to determine the frequency of polymorphic alleles and genotypes of CYP2C19 among them. The review included all the studies that reported data related to the CYP2C19 polymorphisms among Arab populations. The review included Arab CVDs patients who are categorized into carriers (cases) and non-carriers (controls) of CYP2C19 alleles and used clopidogrel as secondary prophylaxis. The patients who had recurrent CVEs or had high on-treatment platelet reactivity (HTPR) while using clopidogrel treatment were described as (events). The results showed a significantly increased risk of recurrent CVDs events by about three folds was associated with carriers of CYP2C19*2 and CYP2C19*3 mutations compared to non-carriers (OR= 3.32, CI=1.94-5.67, and OR=3.53, CI=1.17-10.63 respectively). However, no significant difference was recorded between both studied groups regarding the presence of CYP2C19*17 mutation (OR=0.80, (CI=0.44-1.44). The results also revealed that 59 (4.16%) of Arabs carrying two CYP2C19*2 alleles (homozygous), and 356 (25.12%) have one CYP2C19*2 allele and one CYP2C19*1 allele (heterozygous). Moreover, 42 (2.96%) were carrying two CYP2C19*17 alleles (homozygous), and 262 (18.49%) were carrying one CYP2C19*17 allele and one wild-type allele of CYP2C19 (heterozygous). The most common CYP2C19 genotypes reported among Arabs was the wild-type *1/*1, of which 49.26% of them had the homozygous form of the CYP2C19*1 allele. The frequency of the CYP2C19*1 allele was 71.07%, followed by the CYP2C19*2 allele (16.73%) and CYP2C19*17 (12.21%), respectively. The CYP2C19*3 allele was detected rarely among Arabs (<1%) compared to CYP2C19*1, *2, and *17 alleles. The present study revealed that Arabs carrying CYP2C19*2 and CYP2C19*3 alleles may not respond to clopidogrel and may put those patients at risk of recurrent CVEs. Carriers of the CYP2C19*17 allele, on the other hand, did not show a significant role either in increasing or decreasing the antiplatelet efficacy of clopidogrel. The CYP2C19 genotypes including *1/*1, *1/*2, *1/*17, *2/*2, and *17/*17 are commonly distributed among the Arabs.
1. Background
Patients with cardiovascular diseases (CVDs) are usually caused by a blood coagulation that blocks the cardiac vessels from supplying oxygen, glucose, minerals, and micro minerals to the cardiac tissues. Therefore, patients with CVDs should be subjected to antiplatelet or anticoagulant medications to avoid further coagulation. Otherwise, they will be at high risk of cardiovascular events (CVEs) in the future [1,2].
Clopidogrel is one of the medications that act as an antiplatelet by inhibiting the binding of adenosine diphosphate (ADP) to P2Y12 receptors, thus avoiding platelets adhesions and aggregations [3].
Clinically, clopidogrel is frequently used in Arab countries as a protective agent to avoid recurrent CVEs. However, several clinics did not have specific criteria to monitor the antiplatelet efficacy of clopidogrel either in the short or long term after the dispensation. Globally, the clinical efficacy of clopidogrel is controvertible, as most of the studies suggest that some genetic mutations among specific ethnicities are described as the causes of weak antiplatelet activity. Therefore, pharmacokinetics and pharmacodynamics studies have been conducted to reveal the basis of this issue.
The pharmacokinetic studies showed that clopidogrel prodrug needs to be activated by several metabolic enzymes. The clopidogrel agent is converted to 2-oxo-clopidogrel (inactive metabolite) by CYP1A2, CYP2C19, and CYP2B6 oxidative enzymes. The 2-oxo-clopidogrel is further converted to cis-thiol-clopidogrel (active metabolite) by CYP3A4, CYP2C19, CYP2C9 and CYP2B6 oxidative enzymes [4,5]. Therefore any mutation of these enzymes, including CYP2C19, could affect the metabolism of clopidogrel and consequently affect its plasma concentration levels and efficacy[6].
More than 30 mutations of CYP2C19 have been identified [7]; however, only three polymorphic alleles are more familiar, including CYP2C19*2, CYP2C19*3, and CYP2C19*17. CYP2C19*1 is encoding a normal active form of the CYP2C19 enzyme. CYP2C19*2 and CYP2C19*3 mutant alleles encode an inactive CYP2C19 enzyme, and the CYP2C19*17 mutant allele is known to express a more active form of CYP2C19 enzyme [8].
Previous studies revealed that mutations of CYP2C19 alleles are highly distributed among Asian people but lower among Europeans [9,10]. Nevertheless, the mutations of these alleles are not well studied among the Arab population. Therefore, this study aimed to investigate the efficacy of clopidogrel as an antiplatelet drug among those carrying these alleles and genotypes and determine the frequency of CYP2C19 polymorphic alleles and genotypes among the Arab population.
2. Methods
2.1 Search methods
Two authors independently searched in PubMed, Google Scholar, and EMBASE databases for published English studies at any year related to clopidogrel efficacy and the frequency of CYP2C19 gene polymorphism among Arabs. The exclusion criteria comprised non-Arab populations and patients with any contraindication for clopidogrel. The following terms were used in the search; CYP2C19 Genotypes; OR CYP2C19 Polymorphic alleles; OR CYP2C19 Gene Mutations; AND clopidogrel response; OR Antiplatelet activity; AND Arabs.
2.3 Type of participants
This systematic review (for the qualitative part) included Arab people who were genotyped to determine the frequency of CYP2C19 genotypes and alleles. Concerning the quantitative part (meta-analysis), only patients who previously had CVEs and using clopidogrel as secondary prophylaxis had been included. Those patients were categorized into carriers of (cases) and non-carriers (controls) of CYP2C19 mutations, including CYP2C19*2, CYP2C19*3, and CYP2C19*17.
2.3 Outcome measures
The outcome of the quantitative part was to predict the antiplatelet efficacy of clopidogrel among carriers and non-carriers of CYP2C19 mutations who previously had CVEs through measuring the frequency of the recurrent CVDs or high platelet aggregation reported. The outcome of the qualitative part was to determine the frequency of genotypes and alleles related to the CYP2C19 gene among Arabs.
2.4 Data collection and extraction
Two authors independently reviewed the abstracts of potential articles for inclusion criteria and obtained all the relevant articles. Then, they extracted the following characteristics from the included studies; study setting, duration, design, participants’ age, sex, and outcome measures. Disagreement was solved by discussion.
2.5 Assessment of the risk of bias, quality of evidence, and treatment effect
Two authors independently assessed the risk of bias of the included studies. They graded each risk of bias as high, low, or unclear according to The Newcastle Ottawa Scale for non-randomized Studies [11]. According to the GRADE approach, the quality of evidence for each outcome measure was judged as high, moderate, low, or very low (Grading of Recommendations Assessment, Development, and Evaluation) [12]. The researchers analyzed the data using the Review Manager 5.3 program [13]. The risk of recurrent CVDS events was measured using Odds Ratio (OR) with 95% Confidence Interval (CI).
2.6 Dealing with heterogeneity
The I2 statistic was used to assess heterogeneity among the included studies in each analysis [14].
3. Results
3.1 Results of Search
One hundred and eighty-eight potentially relevant articles were searched, 97 were identified after the removal of duplicates. Two authors independently reviewed the abstracts of the articles based on inclusion and exclusion criteria. Nineteen full-text articles were assessed for eligibility; ten of them met the inclusion criteria (10 in qualitative and 6 in quantitative analysis). Details of the search are given in the PRISMA flow diagram (see figure.1)
3.2 Included Studies
In the quantitative part, the review included 6 observational studies (2 retrospectives, 3 prospective, and one cross-section) [8,15–19], which reported data for clopidogrel antiplatelet efficacy in the presence of different CYP2C19 gene variations.
On the other hand, the qualitative part included 10 studies, four case series, and six observational studies. These ten studies reported the frequency of CYP2C19 polymorphisms among Arabs [20–23].
Two authors independently extracted characteristics of the included studies, including study title, journal, study design, duration, setting, aim, participants’ age, sex, number, and outcome measures (see table.1).
3.3 Trial Participants
The quantitative part of the review included 878 Arabic (Saudis, Egyptians, Jordanians, Tunisians, Iraqis, and Palestinians) patients who were previously diagnosed with CVDs. For the qualitative part, 1417 Arabic people, either healthy or non-healthy, were included. The participants in the qualitative part originated from 7 different Arabic countries, including Saudi Arabia, Egypt, Jordan, Lebanon, Tunisia, Iraq, and Palestine.
3.4 Risk of bias among included Studies
Overall, no high risk of bias was recorded among the included studies in this review. Regarding {adequate case definition} bias and {comparability of cases and control} bias, it was unclear in Rjoub et al. study. Also, the {same representative rate for cases and control} bias was low risk in all included studies. While {consecutive representative of cases} and {independent outcome assessment} bias, it was unclear in most of the included studies (see figure.2).
3.5 Outcomes
3.5.1 Outcomes of the quantitative part
Figures 3,4 and 5 presents the forest plots of the frequency of recurrent CVDs events among Arabic patients using clopidogrel either carrying or not carrying CYP2C19*2, CYP2C19*3, and CYP2C19*17 mutations. The results showed a significantly increased risk of recurrent CVDs events by about three folds was associated with carriers of CYP2C19*2 and CYP2C19*3 mutations compared to non-carriers (OR= 3.32, CI=1.94-5.67, and OR=3.53, CI=1.17-10.63 respectively). However, no significant difference was recorded between both studied groups regarding the presence of CYP2C19*17 mutation (OR=0.80, (CI=0.44-1.44).
3.5.2 Outcomes of the qualitative part
This part included 1417 Arabic people, which were genotyped in order to determine the CYP2C19 gene variations and to detect the availability of any well-known mutated alleles, including CYP2C19*2, CYP2C19*3, and CYP2C19*17 alleles among Arab populations, including Saudis, Egyptians, Jordanians, Iraqis, Palestinians, Lebanese and Tunisians people. The results revealed that 59 (4.16%) of them were carrying two CYP2C19*2 alleles (homozygous), and 356 (25.12%) had one CYP2C19*2 allele and one CYP2C19*1 allele (heterozygous). Moreover, 42 (2.96%) were carrying two CYP2C19*17 alleles (homozygous), and 262 (18.49%) were carrying one CYP2C19*17 allele and one wild-type allele of
CYP2C19 gene (heterozygous)
The most common CYP2C19 genotype reported among Arabs was the wild-type *1/*1, of which 49.26% of them had the homozygous form of the CYP2C19*1 allele. The frequency of the CYP2C19*1 allele was 71.07%, followed by the CYP2C19*2 allele (16.73%) and CYP2C19*17 (12.21%), respectively. The CYP2C19*3 allele was detected rarely among Arabs (<1%) compared to CYP2C19*1, *2, and *17 alleles.
Based on the frequencies of genotypes, about half of Arab people (>49%) could be described as CYP2C19 extensive metabolizers. Other common CYP2C19 gene phenotypes that existed among Arabs are intermediate metabolizers (25%), rapid metabolizers (18%), poor metabolizers (4%), and ultra-rapid metabolizers (3%), respectively.
4. Discussion
Many studies genotyped the CYP2C19 gene to assess clopidogrel’s efficacy among specific ethnic groups. However, few studies correlated CYP2C19 gene mutation and clopidogrel efficacy among Arab ethnic groups.
In the quantitative part, the present study recorded significant differences between carriers (cases) and non-carriers (controls) of CYP2C19*2, *3 alleles regarding the number of recurrent CVEs in Arabs using clopidogrel (OR=3.32, CI=1.94, 5.67, and OR=3.53, CI=1.17, 10.63, respectively). However, there was no statistical difference among carriers and non-carriers of CYP2C19*17 allele concerning the same aspect (OR=0.80, CI=0.44, 1.44).
These results indicate that Arab patients carrying CYP2C19*2 and *3 alleles may decrease the antiplatelet activity of clopidogrel and could lead to recurrent CVEs. The present outcomes were consistent with more than 18 high-quality clinical trials and 6 meta-analysis studies. They revealed that CYP2C19*2 and *3 alleles have a significant role in causing recurrent CVEs among patients using clopidogrel [24–43].
On the other hand, 3 previous meta-analysis studies concluded that loss-of-function alleles (CYP2C19*2 and CYP2C19*3) have no significant effect in causing recurrent CVEs while using clopidogrel. However, they showed a significant effect in leading to other complications (e.g., ST-elevation and stent thrombosis) [44–46]. This could be explained by the presence of other genetic factors that may affect both the clopidogrel bioactivation process and recurrent CVEs, including specific CYP2C9, CYP3A4, CYP1A2, and CYP2B6 genes’ mutations.
Concerning the qualitative part, the study revealed that CYP2C19 genotypes including *1/*1, *1/*2, *1/*17, *2/*2, and *17/*17, respectively, are commonly distributed among Arabs. Compared with other ethnic groups, the CYP2C19*1 allele among Arabs was more or less similar to Caucasians (59.2%), Africans (70.2%), and Asians (65%). Also, the CYP2C19*2 allele is similar to that of Caucasians (15.1%) and Africans (12.6%), but less than Asians (34.5%). The CYP2C19*3 allele was rare among all ethnic groups, except Asians (9%). While the CYP2C19*17 allele represented 12.2% among Arabs, it was recorded as the highest frequent mutant allele among the Caucasian population (25.7%), followed by the Africans (17.2%) and Asians (0.5%) [24].
5. Conclusions
The present study revealed that Arabs carrying CYP2C19*2 and CYP2C19*3 alleles may not respond to clopidogrel and may put those patients at risk of recurrent CVEs. Carriers of the CYP2C19*17 allele, on the other hand, did not show a significant role either in the increase or decrease of the antiplatelet efficacy of clopidogrel. The CYP2C19 genotypes including *1/*1, *1/*2, *1/*17, *2/*2, and *17/*17 are commonly distributed among the Arabs.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Declarations
Conflict of interest
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Availability of data and material
The authors confirm that the data supporting the findings of this study are available within the article.
Competing interests
The authors declare that there is no conflict of interest.
Funding
Not funded.
Author Contributions
AK and NR contributed in conceptualization. AK, NR and NM contributed in writing – original draft preparation. NM, AF, and KA contributed in writing – review and editing. NR, NM, AK, and AF contributed in resources. All authors have read and agreed to the published version of the manuscript.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Acknowledgments
The researchers would like to thank Dr. Yousef Almutairi (Saudi Ministry of Health, Riyadh, Saudi Arabia) for their assistance in reviewing the manuscript.